What disease is Tofacitinib/Shangjie used to treat?

Tofacitinib/Shangjie(Tofacitinib) is an oral small molecule targeted drug widely used in the field of rheumatism and immunity around the world. Its core mechanism of action is to inhibit the JAK (Janus kinase) signaling pathway, thereby reducing the abnormal activity of inflammatory factors. Therefore, it is an immunomodulatory treatment drug rather than an analgesic, hormone or antibiotic in the traditional sense. Tofacitinib is mainly used to treat diseases related to "overreaction of the immune system", the most typical of which are moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis-related diseases and some chronic inflammatory bowel diseases. In overseas clinical practice, it is regarded as "another treatment path after biological agents", especially for patients who have poor response or poor tolerance to traditional immunosuppressants.

Rheumatoid arthritis is one of the diseases for which tofacitinib is most widely used. The cause of this disease is not simple joint wear and tear, but the immune system mistakenly attacks the joint synovium, causing chronic inflammatory pain, morning stiffness, swelling, and even joint destruction. Tofacitinib reduces inflammatory signals by affecting the JAK-STAT pathway, thereby improving pain and limited activity, and helping to slow down further progression of the disease. For patients with psoriatic arthritis, tofacitinib also has a bidirectional effect on inhibiting joint inflammation and skin symptoms. Such patients often face the coexistence of skin plaques and joint pain, and tofacitinib can improve both aspects to a certain extent.

In some countries and regions, tofacitinib is also used in the management of inflammatory bowel diseases such as ulcerative colitis, by relieving intestinal inflammation and improving symptoms such as abdominal pain, diarrhea and bleeding. Its oral form is also widely considered to facilitate long-term use, especially as an alternative for patients who are intolerant to injectable biologics.

Reference materials:https://www.xeljanz.com/